Abstract
Neurofibrillary tangles (NFTs) are one of the pathological hallmarks of Alzheimers disease (AD) and are primarily composed of aggregates of hyperphosphorylated forms of the microtubule associated protein tau. It is likely that an imbalance of kinase and phosphatase activities leads to the abnormal phosphorylation of tau and subsequent aggregation. The wide ranging therapeutic approaches that are being developed include to inhibit tau kinases, to enhance phosphatase activity, to promote microtubule stability, and to reduce tau aggregate formation and/or enhance their clearance with small molecule drugs or by immunotherapeutic means. Most of these promising approaches are still in preclinical development whilst some have progressed to Phase II clinical trials. By pursuing these lines of study, a viable therapy for AD and related tauopathies may be obtained.
Keywords: Tau, therapy, kinases, phosphatase, aggregation, immunotherapy, neurodegenerative disorder, SORL1, PHF, Alz 50, immunoblotting
Current Alzheimer Research
Title: Tau as a Therapeutic Target for Alzheimers Disease
Volume: 8 Issue: 6
Author(s): A. Boutajangout, E. M. Sigurdsson and P. K. Krishnamurthy
Affiliation:
Keywords: Tau, therapy, kinases, phosphatase, aggregation, immunotherapy, neurodegenerative disorder, SORL1, PHF, Alz 50, immunoblotting
Abstract: Neurofibrillary tangles (NFTs) are one of the pathological hallmarks of Alzheimers disease (AD) and are primarily composed of aggregates of hyperphosphorylated forms of the microtubule associated protein tau. It is likely that an imbalance of kinase and phosphatase activities leads to the abnormal phosphorylation of tau and subsequent aggregation. The wide ranging therapeutic approaches that are being developed include to inhibit tau kinases, to enhance phosphatase activity, to promote microtubule stability, and to reduce tau aggregate formation and/or enhance their clearance with small molecule drugs or by immunotherapeutic means. Most of these promising approaches are still in preclinical development whilst some have progressed to Phase II clinical trials. By pursuing these lines of study, a viable therapy for AD and related tauopathies may be obtained.
Export Options
About this article
Cite this article as:
Boutajangout A., M. Sigurdsson E. and K. Krishnamurthy P., Tau as a Therapeutic Target for Alzheimers Disease, Current Alzheimer Research 2011; 8 (6) . https://dx.doi.org/10.2174/156720511796717195
DOI https://dx.doi.org/10.2174/156720511796717195 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Design, Synthesis and Biological Evaluation of Antipicornaviral Pyrrole-Containing Peptidomimetics
Protein & Peptide Letters Metallic Colloid Nanotechnology, Applications in Diagnosis and Therapeutics
Current Pharmaceutical Design Mutations of mtDNA in some Vascular and Metabolic Diseases
Current Pharmaceutical Design The Use of the Inhibitory Receptors for Modulating the Immune Responses
Current Pharmaceutical Design A Coadunation of Biological and Mathematical Perspectives on the Pandemic COVID-19: A Review
Coronaviruses HSV-1-Derived Recombinant and Amplicon Vectors for Gene Transfer and Gene Therapy
Current Gene Therapy Clinical and Therapeutic Challenges when Psychiatric Disorders Occur in Neurological Diseases: A Narrative Review
Current Psychiatry Research and Reviews Current and Future Prospective of a Versatile Moiety: Imidazole
Current Drug Targets Biological Drugs in Guillain-Barré Syndrome: An Update
Current Neuropharmacology Regulation of Innate Immune Responses in the Central Nervous System
CNS & Neurological Disorders - Drug Targets Editorial
Central Nervous System Agents in Medicinal Chemistry Membrane Interacting Peptides: A Review
Current Protein & Peptide Science The Bananins: New Anticorona-RNA-Viral Agents with Unique Structural Signature
Anti-Infective Agents in Medicinal Chemistry Formulation and Characterization of a Ternary Inclusion Complex Containing Hydroxypropyl-β-cyclodextrin and Meglumine for Solubility Enhancement of Poorly Water-Soluble ST-246, an Anti-Smallpox Drug
Current Drug Delivery HIV-1: The Confounding Variables of Virus Neutralization
Current Drug Targets - Infectious Disorders Control of Autoimmune Diseases by the B7-CD28 Family Molecules
Current Pharmaceutical Design Herpetic (Non-Cytomegalovirus) Retinal Infections in Patients with the Acquired Immunodeficiency Syndrome
Current HIV Research Alternative Medicine Safety: Agaricus blazei and Propolis
Combinatorial Chemistry & High Throughput Screening Tetraspanins - Gateways for Infection
Infectious Disorders - Drug Targets Inhibition of Flaviviridae Replication Complex: Assays to Investigate the Modulating Effect of Potential Compounds
Current Enzyme Inhibition